What is Fulcrum Therapeutics, Inc.'s earnings per share (EPS)?

Fulcrum Therapeutics, Inc. (FULC) reported diluted earnings per share of -$1.18 for fiscal year 2025. This represents a -637.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fulcrum Therapeutics, Inc. (FULC) Financials

FULC

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$74.9M -670.0% YoY

EPS (Diluted) -$1.18 -637.5% YoY

Free Cash Flow -$60.4M -2319.0% YoY

Market Cap $281.5M as of Oct 3, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.9x on $310.7M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Sep 2, 2026 Currency USD FYE December

Newest figures come from the S-4 for Q2 FY2026, filed Sep 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FULC SEC filings page.

Fulcrum Therapeutics, Inc. (FULC) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FULC FY2025 2026-10-04

FY2024 revenue jump nearly closed the cash gap, yet sustained R&D spending kept the company loss-making.

FY2024 revenue rose from $2.8M to $80.0M, while operating cash flow improved from -$91.0M to -$2.2M and net loss fell from $97.3M to $9.7M; this indicates revenue materially funded operations rather than merely improving reported earnings. Yet R&D remained $63.4M versus $71.8M in FY2023, so the cash improvement occurred against a still-development-heavy cost base.

The balance sheet is predominantly equity-backed: liabilities were $17.7M against $260.7M of assets, and debt-to-equity was only 0.1x. That structure limits the role of borrowing in financing the reported operations.

With only $278K of capital expenditures versus $63.4M of R&D, cash consumption is research-led rather than driven by factories or equipment. The supplied liquidity comparison equates reported cash, equivalents, and investments to 39.5 months of the latest reported annual operating outflow, a financing position separate from operating profitability.

Financial Health Signals

Financial health score not available

Fulcrum Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

7.87

Fulcrum Therapeutics, Inc. scores 7.87, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($281.5M) relative to total liabilities ($17.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Fulcrum Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Fulcrum Therapeutics, Inc. reported a net loss of $74.9M while operations used $60.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$29.1M

YoY-49.2%

QoQ-33.2%

Fulcrum Therapeutics, Inc.'s EBITDA was -$29.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 49.2% from the same quarter a year earlier. Against the prior quarter it is down 33.2%.

Net Income

-$26.2M

YoY-51.4%

QoQ-38.6%

Fulcrum Therapeutics, Inc. reported -$26.2M in net income in Q2 2026. This represents a decrease of 51.4% from the same quarter a year earlier. Against the prior quarter it is down 38.6%.

EPS (Diluted)

-$0.34

YoY-21.4%

QoQ-36.0%

Fulcrum Therapeutics, Inc. earned -$0.34 per diluted share (EPS) in Q2 2026. This represents a decrease of 21.4% from the same quarter a year earlier. Against the prior quarter it is down 36.0%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$16.1M

YoY-16.3%

QoQ+13.9%

Fulcrum Therapeutics, Inc. recorded an outflow of $16.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 16.3% from the same quarter a year earlier. Against the prior quarter it is up 13.9%.

Cash & Debt

$48.5M

YoY+13.8%

QoQ-3.6%

5Y CAGR-3.1%

Fulcrum Therapeutics, Inc. held $48.5M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

76M

YoY+41.1%

QoQ+14.5%

5Y CAGR+18.5%

Fulcrum Therapeutics, Inc. had 76M shares outstanding in Q2 2026. This represents an increase of 41.1% from the same quarter a year earlier. Against the prior quarter it is up 14.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-8.4%

YoY-0.4pp

QoQ-2.8pp

Fulcrum Therapeutics, Inc.'s ROE was -8.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.8 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$12.4M

YoY-4.2%

QoQ-11.6%

Fulcrum Therapeutics, Inc. invested $12.4M in research and development in Q2 2026. This represents a decrease of 4.2% from the same quarter a year earlier. Against the prior quarter it is down 11.6%.

Capital Expenditures

$108K

YoY+66.2%

QoQ+1250.0%

5Y CAGR-28.2%

Fulcrum Therapeutics, Inc. invested $108K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 66.2% from the same quarter a year earlier. Against the prior quarter it is up 1250.0%.

Share Buybacks

Not reported for Q2 2026.

FULC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FULC quarterly income statement

Metric	TTM	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Revenue	N/A	$0-100.0%	$80.0M+2752.0%	$2.8M-55.8%	$6.3M-66.9%	$19.2M+117.2%	$8.8M	N/A	N/A
R&D Expenses	N/A	$56.1M-11.5%	$63.4M-11.7%	$71.8M-6.5%	$76.8M+10.2%	$69.7M+18.1%	$59.0M-16.9%	$71.1M+182.2%	$25.2M
SG&A Expenses	N/A	$28.7M-21.4%	$36.4M-12.5%	$41.7M-0.1%	$41.7M+36.6%	$30.5M+42.7%	$21.4M+62.7%	$13.1M+58.1%	$8.3M
Operating Income	N/A	-$84.8M-287.1%	-$21.9M+80.2%	-$110.7M+1.7%	-$112.6M-38.9%	-$81.1M-13.2%	-$71.6M+15.0%	-$84.2M-151.4%	-$33.5M
EBITDA	N/A	-$83.4M-310.7%	-$20.3M+81.3%	-$108.5M+1.5%	-$110.1M-40.2%	-$78.5M-13.4%	-$69.2M+15.7%	-$82.2M-155.5%	-$32.2M
Income Tax	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$74.9M-670.0%	-$9.7M+90.0%	-$97.3M+11.4%	-$109.9M-35.9%	-$80.8M-14.2%	-$70.8M+14.3%	-$82.7M-153.7%	-$32.6M
EPS (Basic)	N/A	-$1.18-637.5%	-$0.16+89.9%	-$1.59+34.8%	-$2.44-6.6%	-$2.29+17.9%	-$2.79	N/A	N/A
EPS (Diluted)	-$1.21	-$1.18-637.5%	-$0.16+89.9%	-$1.59+34.8%	-$2.44-6.6%	-$2.29+17.9%	-$2.79	N/A	N/A
Diluted Shares (Avg)	N/A	63M+2.2%	62M+100999.3%	61,310+36.3%	44,991+27.2%	35,361+39.5%	25,354	N/A	N/A

Metric	Q2'26S-4	Q1'26S-4	Q4'25S-4	Q3'2510-Q	Q2'2510-Q	Q1'25S-4	Q4'24S-4	Q3'2410-Q
Revenue	N/A	N/A	N/A	$0	$0-100.0%	N/A	N/A	$0-100.0%
R&D Expenses	$12.4M-4.2%	$14.1M+5.1%	N/A	$14.3M-2.3%	$13.0M-24.8%	$13.4M-32.2%	N/A	$14.6M-19.7%
SG&A Expenses	$7.5M+9.3%	$8.1M+15.8%	N/A	$7.6M-10.2%	$6.8M-33.4%	$7.0M-30.4%	N/A	$8.4M-15.4%
Operating Income	-$29.3M-47.9%	-$22.2M-8.7%	N/A	-$21.9M+13.0%	-$19.8M-137.7%	-$20.4M+31.6%	N/A	-$25.1M+8.4%
EBITDA	-$29.1M-49.2%	-$21.8M-9.0%	N/A	-$21.6M+12.8%	-$19.5M-136.9%	-$20.1M+31.7%	N/A	-$24.7M+8.2%
Net Income	-$26.2M-51.4%	-$18.9M-7.0%	N/A	-$19.6M+9.7%	-$17.3M-131.2%	-$17.7M+34.3%	N/A	-$21.7M+9.7%
EPS (Basic)	-$0.34-21.4%	-$0.25+10.7%	-$0.31-14.8%	-$0.31+11.4%	-$0.28-131.5%	-$0.28+34.9%	-$0.27+32.5%	-$0.35+10.3%
EPS (Diluted)	-$0.34-21.4%	-$0.25+10.7%	-$0.31-14.8%	-$0.31+11.4%	-$0.28-132.2%	-$0.28+34.9%	-$0.27+32.5%	-$0.35+10.3%
Diluted Shares (Avg)	76M+21.9%	76M+22.0%	N/A	63M+0.3%	63M-1.6%	62M+0.8%	N/A	62M+0.9%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

FULC Balance Sheet

FULC quarterly balance sheet

Metric	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$366.3M+40.5%	$260.7M+1.2%	$257.7M+13.7%	$226.7M-3.5%	$235.0M+81.4%	$129.6M+17.3%	$110.4M+28.8%	$85.8M
Current Assets	$357.5M+43.0%	$249.9M+3.2%	$242.2M+16.7%	$207.5M-8.2%	$226.0M+89.1%	$119.5M+19.4%	$100.1M+35.1%	$74.1M
Cash & Equivalents	$197.5M+239.3%	$58.2M+127.7%	$25.6M-27.2%	$35.1M-0.9%	$35.4M-37.9%	$57.1M-41.0%	$96.7M+32.9%	$72.8M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$17.3M-2.3%	$17.7M-21.4%	$22.5M-18.9%	$27.7M+18.3%	$23.5M-31.8%	$34.4M+47.7%	$23.3M-84.4%	$149.4M
Current Liabilities	$13.0M+18.1%	$11.0M-19.2%	$13.7M-18.2%	$16.7M-12.9%	$19.2M-28.2%	$26.7M+120.1%	$12.1M+187.1%	$4.2M
Non-Current Liabilities	$4.2M-36.2%	$6.6M-24.8%	$8.8M-19.9%	$11.0M+158.5%	$4.3M-44.4%	$7.7M-31.2%	$11.1M-92.3%	$145.2M
Total Equity	$349.0M+43.6%	$243.0M+3.3%	$235.2M+18.2%	$198.9M-6.0%	$211.5M+122.2%	$95.2M+9.2%	$87.2M+236.9%	-$63.7M
Retained Earnings	-$594.3M-14.4%	-$519.4M-1.9%	-$509.7M-23.6%	-$412.3M-36.3%	-$302.5M-36.5%	-$221.6M-47.0%	-$150.8M-121.4%	-$68.1M

Metric	Q2'26S-4	Q1'26S-4	Q4'25S-4	Q3'2510-Q	Q2'2510-Q	Q1'25S-4	Q4'24S-4	Q3'2410-Q
Total Assets	$324.0M+41.6%	$346.8M+42.9%	$366.3M+40.5%	$214.9M-23.0%	$228.8M-22.2%	$242.6M+4.3%	$260.7M+1.2%	$279.0M0.0%
Current Assets	$322.9M+47.2%	$338.7M+45.6%	$357.5M+43.0%	$205.9M-23.0%	$219.4M-21.7%	$232.6M+6.7%	$249.9M+3.2%	$267.5M+1.9%
Cash & Equivalents	$48.5M+13.8%	$50.3M+19.2%	$197.5M+239.3%	$47.1M-35.2%	$42.6M-50.9%	$42.2M+5.6%	$58.2M+127.7%	$72.6M+141.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$13.3M-8.3%	$13.5M-4.9%	$17.3M-2.3%	$16.5M-24.1%	$14.5M-29.3%	$14.2M-25.4%	$17.7M-21.4%	$21.7M-7.3%
Current Liabilities	$10.3M+14.6%	$9.9M+21.8%	$13.0M+18.1%	$11.6M-19.8%	$9.0M-29.2%	$8.1M-24.3%	$11.0M-19.2%	$14.5M+3.1%
Non-Current Liabilities	$3.0M-46.0%	$3.6M-40.6%	$4.2M-36.2%	$4.9M-32.6%	$5.5M-29.5%	$6.1M-27.0%	$6.6M-24.8%	$7.2M-22.8%
Total Equity	$310.7M+44.9%	$333.3M+45.9%	$349.0M+43.6%	$198.4M-22.9%	$214.4M-21.7%	$228.5M+7.0%	$243.0M+3.3%	$257.3M+0.7%
Retained Earnings	-$639.3M-15.3%	-$613.2M-14.2%	-$594.3M-14.4%	-$573.9M-14.1%	-$554.3M-15.2%	-$537.1M-0.1%	-$519.4M-1.9%	-$502.8M-3.7%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

FULC Cash Flow Statement

FULC quarterly cash flow statement

Metric	TTM	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$65.8M	-$60.1M-2608.1%	-$2.2M+97.6%	-$91.0M+6.3%	-$97.0M-23.7%	-$78.5M-46.3%	-$53.7M-35.9%	-$39.5M-75.0%	-$22.6M
Depreciation & Amortization	N/A	$1.4M-12.7%	$1.6M-26.7%	$2.2M-10.0%	$2.4M-4.0%	$2.5M+5.7%	$2.4M+15.9%	$2.1M+52.6%	$1.3M
Stock-Based Compensation	N/A	$12.5M-14.3%	$14.6M-1.7%	$14.8M+10.9%	$13.3M+20.6%	$11.1M+50.6%	$7.3M+74.0%	$4.2M+95.6%	$2.2M
Capital Expenditures	$365K	$314K+12.9%	$278K-45.3%	$508K-74.1%	$2.0M+14.6%	$1.7M+27.6%	$1.3M+57.3%	$853K-90.5%	$9.0M
Free Cash Flow	-$66.1M	-$60.4M-2319.0%	-$2.5M+97.3%	-$91.5M+7.6%	-$99.0M-23.5%	-$80.2M-45.8%	-$55.0M-36.3%	-$40.3M-27.9%	-$31.5M
Investing Cash Flow	-$96.9M	$30.7M-4.7%	$32.2M+187.8%	-$36.7M-395.6%	$12.4M+109.6%	-$129.7M-126.9%	-$57.1M-5952.8%	-$944K+89.5%	-$9.0M
Financing Cash Flow	$168.4M	$168.7M+6042.3%	$2.7M-97.7%	$118.1M+40.1%	$84.3M-54.8%	$186.5M+162.2%	$71.1M+10.6%	$64.3M-38.7%	$105.0M
Dividends Paid	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A

Metric	Q2'26S-4	Q1'26S-4	Q4'25S-4	Q3'2510-Q	Q2'2510-Q	Q1'25S-4	Q4'24S-4	Q3'2410-Q
Operating Cash Flow	-$16.0M-16.1%	-$18.8M-22.9%	-$16.8M-0.2%	-$14.2M+25.6%	-$13.8M-123.5%	-$15.3M+39.7%	-$16.8M+27.6%	-$19.1M+16.7%
Depreciation & Amortization	$200K-33.3%	$338K-4.2%	$347K-6.0%	$300K-25.0%	$300K-25.0%	$353K-26.3%	$369K-27.4%	$400K-20.0%
Stock-Based Compensation	$3.3M+13.8%	$3.9M+21.9%	N/A	$3.4M-12.0%	$2.9M-33.8%	$3.2M-19.1%	N/A	$3.8M+2.1%
Capital Expenditures	$108K+66.2%	$8K	$159K-31.2%	$90K+373.7%	$65K	$0-100.0%	$231K+200.0%	$19K-70.8%
Free Cash Flow	-$16.1M-16.3%	-$18.8M-22.9%	-$17.0M+0.2%	-$14.3M+25.2%	-$13.9M-123.6%	-$15.3M+39.7%	-$17.0M+26.9%	-$19.1M+16.9%
Investing Cash Flow	$13.8M-1.1%	-$128.2M-16400.6%	-$1.0M-146.4%	$18.6M+327.9%	$13.9M+211.4%	-$777K-102.0%	$2.3M-87.7%	$4.3M-77.1%
Financing Cash Flow	$356K+18.3%	-$312K	$168.3M+202673.5%	$64K-89.9%	$301K-20.2%	$0-100.0%	$83K-71.1%	$635K
Dividends Paid	$0	$0	$0	$0	$0	$0	$0	$0

Not reported in any period shown, so not listed: Share Buybacks.

FULC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FULC quarterly financial ratios

Metric	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Margin	N/A	-27.4%	-3945.2%	-1774.8%	-423.0%	-811.6%	N/A	N/A
Net Margin	N/A	-12.2%	-3470.2%	-1732.4%	-421.9%	-802.7%	N/A	N/A
Return on Equity	-21.5%-17.5pp	-4.0%+37.4pp	-41.4%+13.8pp	-55.2%-17.0pp	-38.2%+36.2pp	-74.4%+20.5pp	-94.9%	N/A
Return on Assets	-20.4%-16.7pp	-3.7%+34.0pp	-37.8%+10.7pp	-48.5%-14.1pp	-34.4%+20.3pp	-54.6%+20.2pp	-74.9%-36.9pp	-38.0%
Current Ratio	27.40+4.8x	22.63+4.9x	17.71+5.3x	12.41+0.6x	11.77+7.3x	4.47-3.8x	8.24-9.3x	17.52
Debt-to-Equity	0.050.0x	0.070.0x	0.100.0x	0.140.0x	0.11-0.3x	0.36+0.1x	0.27	N/A
Asset Turnover	0.00-0.3x	0.31+0.3x	0.010.0x	0.03-0.1x	0.080.0x	0.07	N/A	N/A
FCF Margin	N/A	-3.1%	-3261.1%	-1561.2%	-418.5%	-623.3%	N/A	N/A

Metric	Q2'26S-4	Q1'26S-4	Q4'25S-4	Q3'2510-Q	Q2'2510-Q	Q1'25S-4	Q4'24S-4	Q3'2410-Q
Return on Equity	-8.4%-0.4pp	-5.7%+2.1pp	N/A	-9.9%-1.4pp	-8.1%-28.3pp	-7.7%+4.9pp	N/A	-8.4%+1.0pp
Return on Assets	-8.1%-0.5pp	-5.5%+1.8pp	N/A	-9.1%-1.3pp	-7.6%-26.4pp	-7.3%+4.3pp	N/A	-7.8%+0.8pp
Current Ratio	31.35+6.9x	34.33+5.6x	27.40+4.8x	17.70-0.7x	24.42+2.3x	28.71+8.3x	22.63+4.9x	18.44-0.2x
Debt-to-Equity	0.040.0x	0.040.0x	0.050.0x	0.080.0x	0.070.0x	0.060.0x	0.070.0x	0.080.0x
Asset Turnover	N/A	N/A	N/A	0.000.0x	0.00-0.3x	N/A	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Fulcrum Therapeutics, Inc. FULC	FY2025	$0	-$74.9M	N/A	$281.5M	—
Lexicon Pharmaceuticals, Inc. LXRX	FY2025	$49.8M	-$50.3M	N/A	$809.8M	65/100
Solid Biosciences Inc. SLDB	FY2025	N/A	-$174.3M	N/A	$734.5M	—
PureTech Health plc American PRTC	FY2025	$4.7M	-$110.1M	N/A	$424.0M	53/100
Autolus Therapeutics plc AUTL	FY2025	$75.4M	-$287.5M	N/A	$473.8M	57/100
Larimar Therapeutics, Inc. LRMR	FY2025	N/A	-$165.7M	N/A	$307.5M	—

Where Fulcrum Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Fulcrum Therapeutics, Inc.'s annual revenue?

Fulcrum Therapeutics, Inc. (FULC) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Fulcrum Therapeutics, Inc.'s revenue growing?

Fulcrum Therapeutics, Inc. (FULC) revenue declined by 100.0% year-over-year, from $80.0M to $0 in fiscal year 2025.

Is Fulcrum Therapeutics, Inc. profitable?

No, Fulcrum Therapeutics, Inc. (FULC) reported a net income of -$74.9M in fiscal year 2025.

What is Fulcrum Therapeutics, Inc.'s EBITDA?

Fulcrum Therapeutics, Inc. (FULC) had EBITDA of -$83.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Fulcrum Therapeutics, Inc.'s return on equity (ROE)?

Fulcrum Therapeutics, Inc. (FULC) has a return on equity of -21.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Fulcrum Therapeutics, Inc.'s free cash flow?

Fulcrum Therapeutics, Inc. (FULC) recorded an outflow of $60.4M in free cash flow during fiscal year 2025. This represents a -2319.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Fulcrum Therapeutics, Inc.'s operating cash flow?

Fulcrum Therapeutics, Inc. (FULC) recorded an outflow of $60.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Fulcrum Therapeutics, Inc.'s total assets?

Fulcrum Therapeutics, Inc. (FULC) had $366.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Fulcrum Therapeutics, Inc.'s capital expenditures?

Fulcrum Therapeutics, Inc. (FULC) invested $314K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Fulcrum Therapeutics, Inc. spend on research and development?

Fulcrum Therapeutics, Inc. (FULC) invested $56.1M in research and development during fiscal year 2025.

How many shares does Fulcrum Therapeutics, Inc. have outstanding?

Fulcrum Therapeutics, Inc. (FULC) had 67M shares outstanding as of fiscal year 2025.

What is Fulcrum Therapeutics, Inc.'s current ratio?

Fulcrum Therapeutics, Inc. (FULC) had a current ratio of 27.40 as of fiscal year 2025, which is generally considered healthy.

What is Fulcrum Therapeutics, Inc.'s debt-to-equity ratio?

Fulcrum Therapeutics, Inc. (FULC) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Fulcrum Therapeutics, Inc.'s return on assets (ROA)?

Fulcrum Therapeutics, Inc. (FULC) had a return on assets of -20.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Fulcrum Therapeutics, Inc.'s P/E ratio?

Fulcrum Therapeutics, Inc. (FULC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $281.5M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Fulcrum Therapeutics, Inc.'s price-to-sales ratio?

Fulcrum Therapeutics, Inc. (FULC) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $281.5M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Fulcrum Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Fulcrum Therapeutics, Inc. (FULC) held $197.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $60.1M over that year. Dividing the one by the other, the reported balance equals about 39 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Fulcrum Therapeutics, Inc.'s Altman Z-Score?

Fulcrum Therapeutics, Inc. (FULC) has an Altman Z-Score of 7.87, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Fulcrum Therapeutics, Inc.'s Piotroski F-Score?

Fulcrum Therapeutics, Inc. (FULC) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Fulcrum Therapeutics, Inc.'s earnings high quality?

Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $74.9M while operations used $60.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.